These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The effect of low calcium diet, mithramycin, and dichlorodimethylene bisphosphonate on humoral hypercalcemia of malignancy in nude mice transplanted with the canine adenocarcinoma tumor line (CAC-8). Rosol TJ; Capen CC J Bone Miner Res; 1987 Oct; 2(5):395-405. PubMed ID: 2971305 [TBL] [Abstract][Full Text] [Related]
5. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms and treatment of hypercalcemia of malignancy. Clines GA Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221 [TBL] [Abstract][Full Text] [Related]
7. Hypercalcemia of malignancy: diagnosis and therapy. Fetchick DA; Mundy GR Compr Ther; 1986 Aug; 12(8):27-32. PubMed ID: 2943551 [TBL] [Abstract][Full Text] [Related]
9. Medical management of the hypercalcemia of malignancy. Deftos LJ; Neer R Annu Rev Med; 1974; 25(0):323-31. PubMed ID: 4277568 [No Abstract] [Full Text] [Related]
10. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Ralston SH; Alzaid AA; Gardner MD; Boyle IT Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513 [TBL] [Abstract][Full Text] [Related]
11. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors. Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357 [TBL] [Abstract][Full Text] [Related]
12. Furosemide, mithramycin, and salmon calcitonin in hypercalcemia. Filastre JP; Humbert G; Leroy J; Maitrot J; Deshayes P; Canonne MA Eur J Intensive Care Med; 1975 Dec; 1(4):185-8. PubMed ID: 130239 [TBL] [Abstract][Full Text] [Related]
13. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.]. Tai N; Inoue D Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007 [TBL] [Abstract][Full Text] [Related]
14. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate. Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of malignancy associated hypercalcemia]. Tai N; Inoue D Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875 [TBL] [Abstract][Full Text] [Related]
16. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Siris ES; Hyman GA; Canfield RE Am J Med; 1983 Mar; 74(3):401-6. PubMed ID: 6219577 [TBL] [Abstract][Full Text] [Related]
17. Comparative study of available medical therapy for hypercalcemia of malignancy. Mundy GR; Wilkinson R; Heath DA Am J Med; 1983 Mar; 74(3):421-32. PubMed ID: 6219578 [TBL] [Abstract][Full Text] [Related]
18. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Harinck HI; Bijvoet OL; Plantingh AS; Body JJ; Elte JW; Sleeboom HP; Wildiers J; Neijt JP Am J Med; 1987 Jun; 82(6):1133-42. PubMed ID: 3300303 [TBL] [Abstract][Full Text] [Related]
19. Immobilization hypercalcemia: a case report and review of the literature. Wolf AW; Chuinard RG; Riggins RS; Walter RM; Depner T Clin Orthop Relat Res; 1976; (118):124-9. PubMed ID: 133782 [TBL] [Abstract][Full Text] [Related]
20. Drug therapy of hypercalcemia due to malignancy. Raue F; Pecherstorfer M Recent Results Cancer Res; 1994; 137():138-60. PubMed ID: 7878293 [No Abstract] [Full Text] [Related] [Next] [New Search]